For GA Treatment, the Earlier the Better

A study from the ARVO 2026 meeting confirms that early intervention for geographic atrophy (GA) using pegcetacoplan (Syfovre) significantly improves long-term outcomes compared to delayed treatment.

Key Study Findings

Researchers analyzed 782 patients transitioning from the two-year OAKS/DERBY trials into the three-year GALE extension study.

  • Superior Tissue Preservation: Patients who started treatment immediately (early group) preserved 3.87 mm² of retinal tissue over five years. Those who started two years late (delayed group) preserved only 1.93 mm².

  • Reduced Growth Rates: In nonsubfoveal GA, monthly injections reduced lesion growth by 33% compared to the sham group.

  • Disease Delay: Continuous five-year therapy delayed the progression of nonsubfoveal GA by approximately 16.5 to 18.5 months.

  • Safety Profile: The treatment remained well-tolerated over five years. Rare instances of retinal vasculitis occurred in fewer than 1 in 4,000 cases, consistent with earlier trial data.

Conclusion

The study concludes that pegcetacoplan is an effective long-term therapy for GA secondary to AMD. The significant difference in tissue preservation between the groups emphasizes that early diagnosis and immediate treatment are critical for saving vision.

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

Keratoconus and Inflammatory Skin Conditions

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH